• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

GSK

GSK HQ London
Biotech

GSK plans ‘some limited impact’ to UK roles from restructuring

GSK’s global restructuring plan is likely to see “some limited impact” to roles on the Big Pharma’s home turf of the U.K., executives have confirmed.
James Waldron Oct 28, 2026 6:33am
ESMO 2026

From RAS rivalry to leaked readouts, ESMO brought the data drama

Oct 27, 2026 8:00am
GSK booth at ASCO 2026

GSK’s B7-H3 ADC drives 67% cancer risk reduction in phase 3

Oct 27, 2026 3:28am
GSK ESMO

ESMO: GSK cancer R&D chief says data ‘reinforces belief’ in mo-rez

Oct 23, 2026 6:05pm
Illustration for Fierces Chutes  Ladders feature showing a blue city skyline with executives making career moves o

GSK's Waterhouse tapped to helm struggling CSL—Chutes & Ladders

Oct 23, 2026 8:30am
GSK

Amid bepirovirsen triumph, GSK scraps trial of next-gen therapy

Oct 21, 2026 9:35am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings